

Subject index Volume 1 (1990)

- A**
- acquired immune deficiency syndrome
 - associated non-Hodgkin's lymphoma in Italy 203
 - chemotherapy and zidovudine in Kaposi's sarcoma 147
 - adenocarcinoma
 - TCNU in adenocarcinoma of the lung 299
 - adjuvant chemotherapy
 - does chemotherapy fulfill its expectations? (special article) 11
 - in breast cancer (editorial) 9
 - in colorectal cancer (commentary) 329
 - late effects of adjuvant oophorectomy and chemotherapy, premenopausal breast cancer patients 30
 - the magnitude of endocrine effects of adjuvant chemotherapy, premenopausal breast cancer patients 183
 - adjuvant oophorectomy
 - late effects of adjuvant oophorectomy and chemotherapy, premenopausal breast cancer patients 30
 - adriamycin
 - constant infusion by ambulatory pump 189
 - AFP
 - value of, in prediction of retroperitoneal lymph node metastases in testis cancer 281
 - AIDS, see acquired immune deficiency syndrome
 - ALL, see leukemia
 - amenorrhoea
 - in adjuvant chemotherapy for premenopausal breast cancer patients 183
 - anti-emetic(s)
 - metoclopramide and methylprednisolone versus metoclopramide alone 379
 - antibiotics
 - empiric treatment of infection during granulocytopenia (review) 255
 - anticancer drugs
 - clonogenic assay with human tumor xenografts 333
 - new targets for (special article) 100
 - of seaweed, mice, and men (editorial) 318
 - ovarian carcinoma xenografts for evaluation of 65
 - aromatase
 - aromatase inhibitors (editorial) 399
 - CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer 421
 - autopsy
 - in modern oncology (commentary) 171
- B**
- B-cell neoplasms
 - minimal residual disease in (special article) 167
 - prognostic significance of immunophenotyping in 45
 - bleomycin
 - with zidovudine in treatment of Kaposi's sarcoma 147
 - bone marrow transplantation,
 - idarubicin and high-dose cytarabine in refractory and relapsed acute lymphoblastic leukemia 51
 - breast cancer
 - a comparison of continuation versus late intensification followed by discontinuation of chemotherapy 36
 - adjuvant systemic therapy (editorial) 9
 - adriamycin by ambulatory pump in 189
 - aromatase inhibitors in (editorial) 399
 - c-erbB-2 protein expression in node negative 263
 - CGS 16949A, a new aromatase inhibitor in 421
 - cisplatin and alpha interferon in 150
 - diagnostic significance of CEA, CA 15-3 and CA 125 in malignant effusions 435
 - epirubicin or epirubicin and vindesine, a Phase III study 275
 - fixed dose short course mitomycin C with vincristine in 373
 - late effects of adjuvant oophorectomy and chemotherapy in premenopausal patients 30
 - link between psychological factors and risk of 22
 - magnitude of endocrine effects of adjuvant chemotherapy for premenopausal patients 183
 - oncogenes and suppressor genes (editorial) 242
 - prevention with an antioestrogen (commentary) 327
 - the process of malignant progression in (special article) 401
 - TMM chemotherapy for metastatic breast cancer 443
- C**
- brequinar
 - Phase II trial with brequinar in colorectal cancer 79
 - CA 15-3
 - in malignant effusions in breast cancer 435
 - CA 125
 - in malignant effusions in breast cancer 435
 - in the early diagnosis of progressive disease in ovarian cancer 301
 - cancer
 - and palliative care (editorial) 396
 - and psyche (editorial) 6
 - cancer incidence in European migrants to New South Wales 219
 - cellular transformation and (special article) 321
 - changes in incidence 293
 - measurement of quality of life 213
 - quality-of-life assessment during a palliative care programme 415
 - cancer care
 - and clinical research (editorial) 95
 - palliative (editorial) 396
 - quality-of-life assessment 415
 - who benefits from Phase I studies (editorial) 164
 - carboplatin
 - cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma 427
 - human ovarian xenografts for evaluation of 65
 - carcinoma
 - of unknown primary: identification of treatable subset? 119
 - of unknown primary site (editorial) 98
 - cardiac toxicity
 - by adriamycin given by ambulatory pump 189
 - of 5-fluorouracil (review) 409
 - CEA
 - in malignant effusions in breast cancer 435
 - cell membrane
 - a new target for anticancer drugs (special article) 100
 - CGS 16949 A

- a new aromatase inhibitor in the treatment of breast cancer 421
- chemotherapy, see also adjuvant chemotherapy
 - * *combination*
 - carboplatin, cisplatin or iproplatin in combination with cyclophosphamide in ovarian cancer 427
 - cisplatin and α -interferon in breast cancer 150
 - cisplatin and α -interferon in non-small cell lung cancer 351
 - cisplatin plus 24-h ifosfamide in advanced malignant melanoma 77
 - epirubicin and vindesine versus epirubicin alone in breast cancer 275
 - etoposide and vindesine with or without cisplatin in small cell lung cancer 128
 - hepatic artery infusion with fluorouracil and mitomycin C in colorectal cancer 227
 - idarubicin and high-dose cytarabine in ALL 51
 - late effects with oophorectomy, premenopausal breast cancer patients 30
 - mitomycin C in fixed dose and vincristine in breast cancer 373
 - salvage chemotherapy in Hodgkin's disease 123
 - TMM chemotherapy in breast cancer 443
 - two regimens of cisplatin plus fluorouracil in advanced squamous cell carcinoma of head-and neck 229
 - vascular toxicity (Raynaud's phenomenon) after combination chemotherapy 289
 - with zidovudine in epidemic Kaposi's sarcoma 147
 - * *general*
 - a comparison of continuation versus late intensification followed by discontinuation in breast cancer 36
 - chemotherapy in B- and T-cell lymphomas 45
 - chemotherapy in lymphoblastic lymphoma 141
 - does chemotherapy fulfill its expectations? (special article) 11
 - in breast cancer (editorial) 9
 - in colorectal cancer (commentary) 329
 - in nasopharyngeal carcinoma (review) 245
 - magnitude of endocrine effects of adjuvant chemotherapy, premenopausal patients 183
 - new targets for (special article) 100
 - potentiation by α -interferon 351
 - salvage chemotherapy in Hodgkin's disease 123
 - sequential versus alternating combination chemotherapy in ovarian cancer 134
 - treatment of germ cell tumours 195
 - * *single agents*
 - 5-fluorouracil: cardiotoxicity (review) 409
 - 5-fluorouracil plus folinic acid: a modified scheme 303
 - adriamycin, constant infusion by ambulatory pump 189
 - bioavailability of subcutaneous ifosfamide 365
 - epirubicin high-dose in non-seminomatous testicular cancer 375
 - epirubicin in breast cancer 275
 - Phase II with brequinar in colorectal cancer 79
 - TCNU in adenocarcinoma of the lung 299
- cimetidine
 - and coumarin in advanced renal cell carcinoma 445
- cisplatin
 - and iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma 427
 - and recombinant α -interferon in advanced breast cancer 150
 - etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer 128
 - human ovarian xenografts in the evaluation of 65
 - magnesium supplementation during administration of 369
 - plus 24-h infusion of ifosfamide in advanced malignant melanoma 77
 - potentiation by α -interferon in advanced non-small cell lung cancer 351
 - treatment of malignant germ cell tumors 195
- clinical research
 - and treatment guidelines (editorial) 95
 - quality of clinical trials (editorial) 319
- clonogenic assay
 - of seaweed, mice, and men (editorial) 318
 - with human tumor xenografts: evaluation, predictive value and application for drug screening 333
- CNS
 - does α -interferon in conjunction with radiotherapy increase the risk of complications in the central nervous system? 449
- colorectal cancer
 - adjuvant treatment (commentary) 329
 - hepatic artery infusion with fluorouracil and mitomycin for metastatic colorectal cancer 227
 - Phase II trial with brequinar 79
- coumarin
 - and cimetidine in advanced renal cell carcinoma 445
- cytarabine
 - and idarubicin in refractory and relapsed acute lymphoblastic leukemia 51
- D**
- doxorubicin, see adriamycin
- drug(s)
 - clonogenic assay and human tumor xenografts 333
 - non-Hodgkin's lymphoma in drug users 203
 - of seaweed, mice, and men (editorial) 318
- drug delivery
 - adriamycin by pump delivery 189
 - dermal infiltrates as a complication of catheter 382
 - prospective trial, a peripheral arm vein, fully implanted venous drug delivery device 82
- E**
- echocardiography
 - cardiotoxicity of 5-fluorouracil (review) 409
 - late cardiac effects after mantle radiotherapy in patients with Hodgkin's disease 355
- effusion
 - diagnostic significance of CEA, CA 15-3 and CA 125 in malignant effusions in breast cancer 435
- emesis
 - cisplatin-induced: randomized study 379
 - emesis during past pregnancy: a new prognostic factor 152
- encephalopathy
 - following ifosfamide 232
- epidemiology
 - cancer incidence in European migrants to New South Wales 219
 - changes in cancer incidence in the Swiss Canton of Vaud, 1978-87 293
 - drinking water during meals and oesophageal cancer: a hypothesis derived from a case-control study in Ethiopia 447
- epirubicin
 - alone or with vindesine in advanced breast cancer 275
 - high-dose in refractory or relapsed non-seminomatous testicular

- cancer 375
- Epstein-Barr Virus
 - in nasopharyngeal carcinoma: (review) 245
- etoposide
 - and vindesine with or without cisplatin in small cell lung cancer 128
- F**
- fluorouracil
 - cardiotoxicity (review) 409
 - effectiveness of hepatic artery infusion 227
 - localized skin toxicity after paravenous infusion 384
 - plus folinic acid: a modified scheme 303
- folinic acid
 - and fluorouracil, a modified scheme 303
 - localized skin toxicity after paravenous infusion with 5-FU 384
- G**
- germ-cell cancer, see also testicular neoplasms
 - mechanism of vascular toxicity in patients with 289
 - treatment of 195
 - value of pre-and postorchietomy serum tumor markers 281
- GM-CSF
 - placebo controlled Phase I/II study of subcutaneous GM-CSF in patients with germ cell tumors undergoing chemotherapy 439
- granulocytopenia
 - empiric treatment with antibiotics (review) 255
- H**
- hairy cell leukemia
 - tubular confronting cisternae in hairy cells following interferon therapy 451
- head and neck tumors
 - two chemotherapy regimens with cisplatin plus fluorouracil in advanced squamous cell carcinoma of the head and neck 229
- heart
 - cardiotoxicity of 5-fluorouracil (review) 409
 - late cardiac effects after mantle radiotherapy in patients with Hodgkin's disease 355
- hepatic artery
 - infusion with fluorouracil and mitomycin for metastatic colorectal cancer 227
- Hodgkin's disease
 - does chemotherapy fulfill its expectations? (special article) 11
 - late cardiac effects after mantle radiotherapy 355
 - salvage chemotherapy 123
- homosexuals
 - AIDS-associated non-Hodgkin's lymphoma in Italy 203
- hormone receptors
 - late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients 30
 - the process of malignant progression in human breast cancer (special article) 401
- hypomagnesemia
 - prevention through intravenous magnesium supplementation 369
- hyponatremia
 - following ifosfamide 232
- I**
- idarubicin
 - and high-dose cytarabine in refractory and relapsed acute lymphoblastic leukemia 51
- ifosfamide
 - and cisplatin in advanced malignant melanoma 77
 - bioavailability of subcutaneous ifosfamide 365
 - encephalopathy following intravenous infusion 232
- immunohistochemistry
 - c-erbB-2 protein expression in node negative breast cancer 263
 - distribution of multi-drug resistance-associated P-glycoprotein 56
- immunophenotype
 - and prognosis in 361 patients with NHL's 45
- immunotherapy
 - coumarin and cimetidine in advanced renal cell carcinoma 445
 - does alpha-interferon with radiotherapy increase CNS-toxicity? 449
 - inflammatory reaction presages response in melanoma 381
 - potentiation by cisplatin in lung cancer 351
 - tubular confronting cisternae in hairy cells following interferon therapy 451
 - with cisplatin in breast cancer 150
 - with subcutaneous interleukin-2 and interferon-a in renal cell cancer 377
- infusion
 - continuous infusion of adriamycin by ambulatory pump 189
- interferon-alpha
 - does alpha-interferon with radiotherapy increase CNS-toxicity? 449
 - inflammatory reaction presages response in melanoma 381
 - potentiation by cisplatin in lung cancer 351
 - tubular confronting cisternae in hairy cells following interferon therapy 451
 - with cisplatin in breast cancer 150
 - with subcutaneous interleukin-2 and interferon-a in renal cell cancer 377
- interleukin-2
 - with interferon-a in renal cell cancer 377
- intravascular coagulation
 - cerebral emboli in chronic intravascular coagulation detected by single photon emission computer tomography 304
- ipropilatin
 - cisplatin, ipropilatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma 427
 - human ovarian xenografts in the evaluation of 65
- K**
- Kaposi's sarcoma
 - treatment of epidemic Kaposi's sarcoma with combination chemotherapy 147
- L**
- late effects
 - late cardiac effects after mantle radiotherapy in patients with Hodgkin's disease 355
- leukemia,
 - acute lymphoblastic: idarubicin and high-dose ARA-C 51
 - lymphoblastic lymphoma treated as 141
 - minimal residual disease (special article) 167
 - tubular confronting cisternae in hairy cells following interferon therapy 451
- linear analogue scale
 - measurement of quality of life during cancer chemotherapy 213

- lung cancer
 - cisplatin and alpha-interferon in advanced non-small cell lung cancer 351
 - etoposide and vindesine with or without cisplatin in small cell lung cancer 128
 - TCNU in adenocarcinoma 299
- lung metastases
 - results of salvage surgery for metastatic sarcomas 269
- lymphoma
 - AIDS-associated non-Hodgkin's lymphoma in Italy 203
 - analysis of 12 cases involving testis 383
 - clinico-pathological analysis of 33 cases of bone involvement 450
 - dermal infiltrates as complication of catheter 382
 - immunophenotyping in, prognostic significance 45
 - lymphoblastic lymphoma in adults treated similarly to ALL 141
 - minimal residual disease (special article) 167
- M**
- melanoma
 - cisplatin plus 24-hour infusion of ifosfamide in advanced malignant melanoma 77
 - inflammatory reaction to alpha-interferon presages response 381
- meta analysis
 - quality of clinical trials (editorial) 319
 - randomized clinical trials and their influence on the treatment of advanced epithelial ovarian cancer 343
- methylprednisolone
 - randomized study of metoclopramide and methylprednisolone versus metoclopramide alone 379
- metoclopramide
 - randomized study of metoclopramide and methylprednisolone versus metoclopramide alone 379
- migrant
 - cancer incidence in European migrants to New South Wales 219
- mitomycin-c
 - adjuvant treatment of colorectal cancer (commentary) 329
 - fixed dose short course with vincristine in breast cancer 373
 - hepatic artery infusion with fluorouracil and mitomycin for metastatic colorectal cancer confined to the liver 227
- mitoxantrone
 - TMM chemotherapy for metastatic breast cancer 443
- monoclonal antibodies
 - distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues, analysis with 3 monoclonal antibodies 56
- multi-drug resistance
 - distribution of multi-drug resistance-associated P-glycoprotein 56
- myocardial infarction
 - 5-fluorouracil cardiotoxicity (review) 409
- N**
- nasopharynx
 - nasopharyngeal carcinoma: a medical oncology viewpoint (review) 245
 - two chemotherapy regimens with cisplatin plus fluorouracil in advanced squamous cell carcinoma of the head and neck 229
- neoadjuvant chemotherapy
 - does chemotherapy fulfill its expectations? 11
- nude mice
 - of seaweed, mice and men (editorial) 318
 - the clonogenic assay with human tumor xenografts: evaluation, predictive value and application for drug screening 333
- O**
- oesophageal cancer
 - drinking water during meals and oesophageal cancer: a hypothesis derived from a case-control study in Ethiopia 447
- oncogenes
 - and breast cancer (editorial) 242
 - c-erbB-2 expression in breast cancer 263
 - transcriptional control and cellular transformation (special article) 321
- oophorectomy
 - adjuvant treatment of breast cancer (editorial) 9
 - late effect of adjuvant oophorectomy in premenopausal patients 183
- osteosarcoma
 - superior vena cava syndrome 81
- ovarian carcinoma
 - a randomized study of sequential versus alternating combination chemotherapy 134
 - c-erbB-2 expression in breast cancer 263
 - cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma 427
 - human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs 65
 - quality and development of randomized clinical trials 343
 - quality of cancer clinical trials (editorial) 319
 - role of CA 125 in the early diagnosis of progressive disease 301
 - the impact of cancer treatment guidelines on actual practice in Italian general hospitals: the case of ovarian cancer 112
 - transcriptional control and cellular transformation (special article) 321
- P**
- palliative care
 - palliative care in oncology (editorial) 396
 - quality-of-life assessment during a palliative care programme 415
- perioperative therapy
 - the magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients 183
- pharmacokinetic
 - bioavailability of subcutaneous ifosfamide 365
- Phase I
 - CGS 16949A a new aromatase inhibitor in the treatment of breast cancer 421
 - responses and toxic deaths in 175
 - who benefits? (editorial) 164
- Phase II
 - chemotherapy and zidovudine in Kaposi's sarcoma 147
 - cisplatin and alpha-interferon in breast cancer 150
 - cisplatin and alpha-interferon in non-small cell lung cancer 351
 - cisplatin plus 24-h infusion ifosfamide 77
 - constant continuous infusion of adriamycin in breast cancer 189
 - fixed dose of mitomycin C in advanced breast cancer 373
 - hepatic artery infusion 227
 - high-dose epirubicin in testicular cancer 375

- interleukin-2 and alpha-interferon in renal cell cancer 377
 - Phase II trial with brequinar in metastatic colorectal cancer 79
 - subcutaneous GM-CSF versus placebo 439
 - TCNU in adenocarcinoma of the lung 299
 - platinum, see cisplatin, carboplatin, iproplatin
 - polymerase chain reaction (PCR)
 - and minimal residual disease (special article) 167
 - potentiation
 - potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer (NSCLC) 351
 - prevention
 - prelude to breast cancer prevention with an antioestrogen (commentary) 327
 - prognostic factors
 - c-erbB-2 protein expression in node negative breast cancer 263
 - carcinoma of unknown origin: identification of a treatable subset? 119
 - emesis during past pregnancy: a new prognostic factor in chemotherapy-induced emesis 152
 - immunophenotype in malignant lymphomas 45
 - in malignant effusions in breast cancer 435
 - in the early diagnosis of progressive disease in ovarian cancer 301
 - serum markers in testicular cancer 281
 - psyche
 - and risk of breast cancer 22
 - psyche and cancer (editorial) 6
 - who benefits from Phase I studies (editorial) 164
 - psychosomatic factors
 - evidence for a link between certain psychological factors and the risk of breast cancer in a case-control study 22
 - psyche and cancer (editorial) 6
- Q**
- quality of care
 - palliative care in oncology (editorial) 396
 - quality-of-life assessment during a palliative care programme 415
 - the impact of cancer treatment guidelines 112
 - who benefits from Phase I studies? (editorial) 164
 - quality of life
 - measurement of quality of life during cancer chemotherapy 213
 - quality-of-life assessment during a palliative care programme 415
- R**
- radiotherapy
 - does alpha-interferon increase CNS toxicity? 449
 - in nasopharyngeal carcinoma (special article) 245
 - late cardiac effects after mantle radiotherapy in patients with Hodgkin's disease 355
 - with chemotherapy in breast cancer 36
 - Raynaud's phenomenon
 - in patients treated with cisplatin, vinblastine and bleomycin 289
 - receptors
 - * *hormonal*
 - late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients 30
 - the process of malignant progression in human breast cancer (special article) 401

- * *nuclear*
 - cell membrane and cell signals (special article) 100
 - transcriptional control and cellular transformation (special article) 321
- renal cell cancer
 - Phase II trial of coumarin and cimetidine in advanced renal cell carcinoma 445
 - treatment with interleukin-2 and alpha-interferon 377
- resistance
 - minimal residual disease in leukaemia and lymphoma 167
 - of seaweed, mice, and men 318
 - results of salvage surgery for metastatic sarcomas 269
 - salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission 123
 - the clonogenic assay with human tumor xenografts: evaluation, predictive value and application for drug screening 333
 - the establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs 65

S

- salvage
 - salvage chemotherapy in Hodgkin's disease 123
 - salvage surgery for metastatic sarcomas 269
 - sarcomas
 - results of surgery for metastatic sarcomas 269
 - surgery for lung metastases (editorial) 244
 - screening
 - clonogenic assay with human tumor xenografts 333
 - human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs 65
 - new targets for (special article) 100
 - of seaweed, mice, and men (editorial) 318
 - ovarian carcinoma xenografts for evaluation of 65
 - serum marker
 - in malignant effusions in breast cancer 435
 - the role of CA 125 in the early diagnosis of progressive disease in ovarian cancer 301
 - value of, in prediction of retroperitoneal lymph node metastases in testis cancer 281
 - signal transduction
 - the cell membrane and cell signals: new targets for novel anticancer drugs 100
 - SPECT
 - cerebral emboli in chronic intravascular coagulation detected by 304
 - suppressor genes
 - and breast cancer (editorial) 242
 - surgery
 - for lung metastases of sarcomas (editorial) 244
- T**
- T-cells
 - peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas 45
 - TCNU
 - TCNU in adenocarcinoma of the lung: a Phase II study with divided doses 299
 - terminal patient(s)
 - palliative care in oncology - making quality the endpoint 396
 - quality-of-life assessment during a palliative care programme 415
 - who benefits from Phase I studies, (editorial) 164

testicular neoplasms

- an analysis of 12 cases of lymphomas of the testis 383
- high dose epirubicin in refractory or relapsed non-seminomatous testicular cancer 375
- placebo controlled Phase I/II study of subcutaneous GM-CSF in patients with germ cell tumors undergoing chemotherapy 439
- serum markers in early stages 281
- treatment of 195

thiotepa

- TMM chemotherapy for metastatic breast cancer 443

toxic deaths

- responses and toxic deaths in Phase I clinical trials 175

treatment guidelines

- and clinical research (editorial) 95

tubular function

- intravenous magnesium supplementation during cisplatin-dichloroplatinum administration prevents hypomagnesemia 369

tumor markers, see serum markers

V

validation

- on the receiving end-III. Measurement of quality of life during cancer chemotherapy 213

vincristine

- in lymphoblastic lymphoma in adults 141
- treatment of epidemic Kaposi's sarcoma with combination chemotherapy (vincristine and bleomycin) and zidovudine 147

vindesine

- epirubicin or epirubicin and vindesine in advanced breast cancer 275
- etoposide and vindesine with or without cisplatin in small cell lung cancer 128

X

xenografts

- of seaweed, mice and men 318
- the establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs 65

Z

zidovudine (ZDV)

- treatment of epidemic Kaposi's sarcoma with combination chemotherapy (vincristine and bleomycin) and zidovudine 147

Author index Volume 1 (1990)

- A**
 Abad A 379
 Aeberhard P 227
 Ahmedzai S 396
 Åkerman M 355
 Alexanian A 112
 Allan SG 351
 Amadori S 51
 Amoroso D 150
 Andersen E 275
 Anderson E 242
 Anderson H 427
 Apolone G 112
 Armand JP 245
 Assadourian R 382
 Astini C 447
 Atzpodien J 377
 Azli N 245
 Azzarelli A 269
- B**
 Bacchi M 36
 Bach F 299
 Bachouchi M 245
 Barriga JJ 379
 Basurto C 381
 Baziotis N 435
 Becquart D 81, 128
 Begg CB 319
 Beretta KR 421
 Berger DP 333
 Berger F 45
 Berger MS 263
 Bernasconi C 141
 Bernstein-Singer M 147
 Bertelli G 150
 Bhardwaj S 443
 Bhatnagar AS 421
 Bisagni G 36
 Blanc AP 382
 Blomkvist E 449
 Bokemeyer C 375
 Bonadonna G 11, 123
 Bonfante V 123
 Borner M 227
 Boussen H 245
 Bourgeois N 81
 Bowman A 351
 Bracarda S 381
 Brousse N 45
 Broxterman HJ 56
 Brunner KW 227, 365
 Brünner N 401
 Brusamolino E 141
 Bryon PA 45
 Buckley CH 427
 Bureau G 128
 Burk K 375
- Buzzi F** 36
- C**
 Canaletti R 36
 Cantwell BMJ 232, 373
 Carella AM 51
 Carotenuto M 51
 Carpi A 36
 Carrieri MP 447
 Casali P 269
 Castiglione M 183, 227
 Cavalli F 79, 164, 227, 421
 Ceci G 36
 Cerny T 365
 Chaudri HA 421
 Chiu E 383, 450
 Clarke R 401
 Coates A 213
 Coates MS 219
 Cocconi G 36
 Coiffier B 45
 Colella R 51
 Colozza A 36
 Compagnucci M 112
 Cornbleet MA 351
 Cotter FE 167
 Crompton GK 351
 Crowther D 427
 Cvitkovic E 245
- D**
 Dabuis G 128
 Daugaard G 195
 De Conno F 415
 De Lisi V 36
 De Mulder PHM 369
 Decoster G 175
 Dees A 304
 Degryse H 81
 Denz H 303
 Descorps-Declere A 189
 Desta A 447
 Di Mambro E 112
 Diaz-Rubio E 152, 379
 Dickson RB 401
 Diebold J 45
 Dirix L 81
 Dodion PF 79
 Dörlken G 375
 Dombrowsky P 275, 299
 Domenge C 245
 Doria F 447
 Drozd A 79
- E**
 Ecstein E 189
 Efremidis AP 435
- Engelholm SA** 275
 Eriksson B 449
 Eschwege F 245
 Eskilsson J 355
- F**
 Ferderigou A 435
 Fergusson RJ 351
 Fiebig HH 333
 Flodgren P 281
 Flury R 82
 Foà R 203
 Focarile F 343
 Ford JM 219
 Fosså SD 281
 Fossati R 112
 Franks CR 377
 Franzosi MG 343
- G**
 Gamba A 415
 Gambino A 343
 Gasmi J 245
 Gasparini M 269
 Gelber RD 183, 263
 Gerber HA 263
 Gil-Delgado MA 189
 Gill PS 147
 Giona F 51
 Gisin H 303
 Gisselbrecht C 45
 Glasziou P 213
 Gloor F 227
 Goldhirsch A 30, 183, 263, 421
 Gonzalez-Larriba JL 379
 Gozda A 150
 Gradishar WJ 409
 Grazzini G 112
 Greco FA 98
 Greening AP 351
 Gregor A 351
 Grilli R 112, 343
 Groner B 263, 321
 Grotto P 51
 Gudat F 451
 Gullick WJ 263
 Gurney H 427
 Gustavsson A 355
- H**
 Haenggi ST 384
 Hagberg H 449
 Hainsworth JD 98
 Hall G 232
 Hansen HH 134, 195, 299
 Hansen M 134, 275
 Hansen SW 289
 Harrap KR 65

Harstrick A 375
 Heiman D 384
 Henderson IC 9
 Hendrick A 373
 Hennig FW 445
 Henss H 333
 Henzen-Logmans SC 119
 Herrmann R 445
 Herzberg R 22
 Hoeffken K 421
 Holdener EE 175
 Holland JF 443
 Howell T 242
 Hüry C 6
 Hurwitz N 451
 Hynes NE 263

I

Idle M 232
 International Breast Cancer Study Group
 30

J

Jasmin C 22, 189
 Jensen J 275
 Jones B 147
 Jones M 65
 Jordan VC 327
 Jost LM 439

K

Kandylis K 435
 Kelland LR 65
 Ketelaars H 56
 Kiegel P 382
 Kirchner H 377
 Klastersky J 128, 255
 Klepp O 281
 Klijanenko J 245
 Kohler BEM 369
 Köhli K 82
 Köhne Wömpner C 375
 Körfer A 377
 Kuiper CM 56
 Kùpfer A 365
 Kvinnsland S 421

L

La Vecchia C 293
 Laffer U 227
 Lammes FB 301
 Landberg T 355
 Lankelma J 56
 Lazzarino M 141
 Lê MG 22
 Lecomte J 128
 Leonard RCF 351
 Leoni P 51
 Lev LM 79
 Levi F 293
 Levine AM 147
 Liang R 383, 450
 Liati P 343

Liberati A 112, 343
 Libert P 128
 Lilja A 449
 Lind MJ 232
 Lindholm CE 281
 Lister TA 167
 Litzistorf Y 451
 Locher GW 263
 Loke SL 383, 450
 Lottici R 36
 Ludwig C 227, 303
 Lund B 134
 Lundvall F 134

M

Maartman-Moe H 281
 Mandelli F 51
 Manegold C 445
 Marini G 150
 Marino JP 189
 Marsoni S 112, 343
 Martin M 152, 379
 Marty P 22
 Matthiessen W 445
 Maurer B 445
 Mayor P 427
 McCredie M 219
 McNeil D 213
 Meeuwis CM 229
 Meijer CJL 56
 Meinecke D 82
 Mele A 447
 Meloni G 51
 Mesi L 112
 Metzger U 227
 Micheau C 245
 Michel J 128
 Millward MJ 232, 373
 Miniero R 51
 Missel JL 189
 Mommen P 128
 Monfardini S 203
 Montgomery T 147
 Morra E 141
 Muhr C 449
 Murphy D 427

N

Negretti E 123
 Netten PM 369
 Nicolucci A 112
 Nielsen D 275
 Nielsen NC 134

O

Obrecht JP 227, 303, 384
 Obrist R 227, 384
 Oeberg K 449
 Olsen N 289
 Olsson Y 449

Orlandi E 141
 Osborn J 447

P

Paesmans M 128
 Pagnucco G 141
 Palmer PA 377
 Palmieri D 112
 Papadimitriou A 435
 Parazzini F 343
 Pasquini P 447
 Passalacqua R 36
 Pastorino U 269
 Paus E 281
 Peracchia G 36
 Persson L 449
 Peuchmaur M 45
 Pichert G 439
 Pinedo HM 56
 Pistotti V 343
 Planting ASTh 77, 229
 Poliwóca H 375, 377
 Pollard LA 65
 Ponten U 449
 Prendiville J 427
 Price C 167
 Pronzato P 150
 Psycho-Oncologic Group 22

R

Rahal M 245
 Ranson M 427
 Rarick MU 147
 Ravasi G 269
 Ravez P 128
 Renard J 79
 Resegotti L 51
 Richner J 263
 Rinderknecht BP 451
 Ripamonti C 415
 Rodenburg CJ 119, 304
 Roila F 381
 Rørth M 195, 289
 Rosell R 379
 Rossing N 289
 Rosso R 150
 Routy JP 382
 Rüst H 82

S

Saccani Jotti G 171, 305
 Santoro A 123, 269
 Sauter G 451
 Scheffer G 56
 Schepers RJ 56
 Schmerber J 128
 Schmid L 82
 Schmitz PIM 229
 Schmoll HJ 375
 Schöber C 375

Schönfeld DHW 304
Schwaab G 245
Sculier JP 128
Senn HJ 82, 227
Sergysels R 128
Sessa C 164
Simes RJ 95
Siracky J 65
Skovsgaard T 79, 275
Smyth JF 351
Sørensen BL 134
Sørensen JB 299
Stahel RA 439
Stahl M 375
Stein G 175
Stewart ME 351
Stoter G 77, 79, 119, 229
Sudan N 382
Svahn-Tapper G 355
Swindell R 427

T

Taiana A 343
Tamburini M 415
Tattersall MHN 95
Tavecchio L 269
Te VC 293
Teigum H 281
Testi AM 51

Theeuwes AG 369
Thiriaux J 128
Thomsen HK 134
Tindall VR 427
Tirelli U 203
Tonato M 381
Tonini G 112
Torri W 112, 343
Trunet P 421
Tsoussis S 435
Tsuruo T 56

U

Unsgaard B 281

V

Vaccher E 203
Valagussa P 123
Valente M 269
Valerdi JJ 379
Van der Burg MEL 301
Van der Gaast A 77, 119
Van der Valk P 56
Van Kalken CK 56
Van Oosterom AT 81, 244
Van Sicheem CK 229
Vandermoten G 128
Vanmaele R 81
Vassilomanolakis M 435

Vecht CJ 304
Ventafridda V 415
Verweij J 77, 119, 229, 301
Vibe-Petersen J 299
Viviani S 123
Vokes EE 409
von Hoff DD 318

W

Wagener DJTh 79, 329, 369
Weber W 227
White T 355
Wibault P 245
Wilke H 375
Willems JL 369
Wils J 329
Winterhalter BR 333
Wollmer P 355
Workman P 100, 235

Y

Young BD 167

Z

Zaniboni A 150
Zeugin T 365
Zola P 112